KR920006298A - 피브리노겐 수용체 길항제 - Google Patents
피브리노겐 수용체 길항제 Download PDFInfo
- Publication number
- KR920006298A KR920006298A KR1019910016837A KR910016837A KR920006298A KR 920006298 A KR920006298 A KR 920006298A KR 1019910016837 A KR1019910016837 A KR 1019910016837A KR 910016837 A KR910016837 A KR 910016837A KR 920006298 A KR920006298 A KR 920006298A
- Authority
- KR
- South Korea
- Prior art keywords
- propionic acid
- phenyl
- mammal
- compound
- alkyl
- Prior art date
Links
- 239000002319 fibrinogen receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 208000007536 Thrombosis Diseases 0.000 claims abstract 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract 6
- 102000008946 Fibrinogen Human genes 0.000 claims abstract 5
- 108010049003 Fibrinogen Proteins 0.000 claims abstract 5
- 229940012952 fibrinogen Drugs 0.000 claims abstract 5
- 241000124008 Mammalia Species 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 19
- -1 1-ethenyl Chemical class 0.000 claims 18
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 claims 15
- 239000003937 drug carrier Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 208000005189 Embolism Diseases 0.000 claims 13
- 239000003146 anticoagulant agent Substances 0.000 claims 11
- 229940127219 anticoagulant drug Drugs 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 235000019260 propionic acid Nutrition 0.000 claims 9
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 239000003527 fibrinolytic agent Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229960000103 thrombolytic agent Drugs 0.000 claims 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- YYFIGOPUHPDIBO-UHFFFAOYSA-N propanoic acid;hydrochloride Chemical compound Cl.CCC(O)=O YYFIGOPUHPDIBO-UHFFFAOYSA-N 0.000 claims 3
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000006550 alkoxycarbonyl aryl group Chemical group 0.000 claims 1
- 125000004685 alkoxythiocarbonyl group Chemical group 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 150000001735 carboxylic acids Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C325/00—Thioaldehydes; Thioketones; Thioquinones; Oxides thereof
- C07C325/02—Thioketones; Oxides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (36)
- 하기 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용가능한 염.상기 식에서 R1은, 1,2,3 또는 4개의 헤테로원자를 함유하는 4내지 8원의 헤테로사이클릭 환헤테로사이클릭 환은(여기에서 헤테로 원자는 N, O 또는 S이며, 헤테로 사이클릭 환은 어떤 원자에서든 H, R6또는 R7에 의해 임의로 치환된다.NR6R7[여기에서, R6및 R7은 독립적으로 수소, C1-10알콕시카보닐 또는 비치환 또는 치환된 C1-10알킬 및 사이클로알킬이며, 여기에서, 치환체는, C1-10알콕시, C1-10알콕시알킬, C1-10알콕시알킬옥시,C1-10알콕시카보닐, C1-10알킬카보닐, C0-5알킬아미노카보닐, C1-10아르알킬카보닐, C4-10아르알킬티오카보닐 티오카보닐, C1-10알콕시티오카보닐, 아릴, 1,2,3 또는 4개의 헤테로원자를 함유하는 5내지 6원 포화 헤테로사이클릭 환(여기에서, 상기 헤테로원자는 N, 0 및 S중에서 선택된다), C1-4알카노일아미노, C1-6알콕시카보닐-C0-6알킬아미노, C1-10알킬설포닐아미노, C4-10아르알킬설포닐아미노, C4-10아르알킬, C1-10알크아릴, C1-10알킬티오, C4-10아르알킬티오, C1-10알킬설피닐, C4-10아르알킬설피닐, C1-10알킬설포닐, C4-10아르알킬설포닐, 아미노설포닐, C1-10알킬아미노설포닐, C4-10아르알킬설포닐 아미노, 옥소, 티오, 비치환 또는 일-또는 이치환된 1-에테닐, 2-에테닐, 2-에테닐 또는 3-프로페닐(여기에서, 치환체는 수소, C1-10알킬, 및 C7-10아르알킬 중에서 선택된다.카복시, 하이드록시, 아미노, C1-6알킬아미노, C1-6디알킬아미노,할로겐(여기에서 할로겐은 C1, F, Br, 또는 I이다). 니트로 또는 시아노이며, 또한 N은 상기에서 R6및 R7에 대해 정의한 바와 같은 치환체에 의해 추가로 치환되어 4급 암모늄 이온을 형성할수 있다]이고; R2및 R3는 독립적으로 수소, 아릴 또는 비치환 또는 치환된 C1-10알킬 또는 사이클로알킬, [여기에서, 치환체는 C1-10알콕시알킬, 아릴, 1,2,3 또는 4개의 헤테로원자를 함유하는 내지 8원의 헤테로사이클릭 환(여기에서, 상기 헤테로원자는, N, O 및 S중에서 선택된다.)C4-10아르알킬, C1-10알크아릴, 카복시, C1-10알킬카보닐, C1-10알킬티오카보닐, C4-10아르알킬카보닐, C4-10아르알킬티오카보닐, C1-5알콜시카보닐, C4-10아르알콕시카보닐, C1-5알콕시, C4-10아르알콕시, C1-5알킬아미노, C1-12디알킬아미노, C1-5알킬아미노, C4-12아르알카노일아미노, C4-10아르알킬아미노이다]이고;R4는 수소, 아릴, C1-10알킬 또는 사이클로알킬, C4-10아르알킬, 아릴카보닐, 아미노카보닐, C1-10알킬카보닐, C1-6알킬아미노카보닐, C1-10알킬티오카보닐, C1-6디알킬아미노, 카보닐, C1-10알콕시티오카보닐, 아릴 C1-6알킬아미노카보닐, C1-10알콕시카보닐, C4-10아르알킬카보닐, C4-10아르알콕시카보닐, C1-10카복시알킬이고, 또한 치환체 R4는 ,R6에 대해 정의 한 그룹으로 부터 선택된 하나 이상의 치환체 또는 아미드 결합에 의해 연결된 L-또는 D-아미노산에 의해 치환될수 있으며; R5는 1,2,3 또는 4개의 헤테로원자를 함유하는 4내지 8원의 포화 또는 불포화 헤테로사이클릭 환(여기에서, 헤테로원자는 N, O 또는 S이다), 또는[여기에서, R8은 하이드록시, C1-10알킬옥시, C1-10알크아릴옥시, C4-10아르알킬옥시, C4-10아르알킬카보닐옥시, C1-10알콕시알킬옥시, C1-10알콕시알킬카보닐옥시, C1-10알콕시카보닐옥시알킬, C1-10알킬카보닐옥시알킬옥시 및 아미드 결함에 의해 연결된 L-또는 O-아미노산(여기에서, 이미노산의 카복실산 잔기는 유리산 이거나 C1-5알킬에 의해 에스테르화된다)이다],또는(여기에서 R9및 R10은 수소, C1-10알킬 및 C4-10아르알킬 중에서 선택된다)이고; X 및 Y는 독립적으로 NR6, O, SO, SO2,옥소, 아릴, 티오노, 비치환 또는 치환된 C1-15알킬 또는 사이클로알킬[여기에서, 치환체는 독립적으로 R6및 R7이다),SO2-, SO2-NR6-, 또는 1,2,3 또는 4개의 헤테로원자를 함유하는 4내지 8원의 헤테로사이클릭 환(여기서, 헤테로원자는, N, O 및 S이고, 환은 독립적으로 어떤 원자에서 R6로 치환된다)]이며; Z는 임의의 치환체이며, 존재할 경우, X 및 Y에 대해 정의한 그룹중에서 독립적으로 선택되고 ; m은 0내지 10의 정수이고; n은 0내지 10의 정수이며; p는 0내지 3의 정수이다.
- 하기 일반식(Ⅱ)의 화합물 및 이의 약제학적으로 허용가능한 염,상기 식에서 R1은, 1,2,3 또는 4개의 헤테로원자를 함유하는 4내지 8원의 헤테로사이클릭 환(여기에서 헤테로 원자는 N, O 또는 S이며, 헤테로 사이클릭 환은 수소, C1-10알킬에 의해 임의로 치환된)또는 NR6R7[여기에서 R6및 R7은 독립적으로, 수소, C1-10알콕시카보닐 또는 비치환 또는 치환된 C1-10알킬 (여기에서, 치환체는 C1-10알콕시 C1-10알콕시카보닐 아릴, C4-10아르알킬, C1-10알크아릴 카복시, 하이드록시 또는 아미노이다)].(여기에서, N은 추가로 치환되어 4급 암모늄 이온을 형성할수 있다)이고; R2및 R3는 독립적으로, 수소, C1-10알콕시카보닐, C1-10알콕시카보닐, C4-10아르알킬카보닐 또는 C4-10아르알콕시카보닐이고, 또한 치환체 R4는 제1항에서 R6로서 정의된 그룹으로부터의 하나 이상의 치환체로 치환될수 있으며, R11은 수소 또는 C1-10알킬이고, X 및 Y는 독립적으로, O, S, SO, SO2, 아릴, -CH=CH-, 옥소, -C-NR6, 또는NR6SO2, -SO2NR6-, 비치환 또는 치환된 C1-15직쇄 또는 측쇄 알킬(여기에서, 치환체는 카복시, 하이드록시, C1-10알콕시, 또는 N, O또는 S로부터 선택된, 1, 2 또는 3개의 헤테로원자를 함유하는 4- 내지 6-원 헤테로 사이클릭 환이다)이며; Z는 임의의 치환체이며, 존재할 경우, O, SO2, NR6CO, CONR6,이며; m은 0내지 6의 정수이고 ; n은 0내지 6의 정수이며; p는 0내지 3의 정수이다.
- 하기 일반식(Ⅱ)의 화합물 및 이의 약제학적으로 허용가능한 염.상기 식에서 R1은, 1 또는 2개의 헤테로원자를 함유하는 5내지 6원의 헤테로사이클릭 환환(여기에서 헤테로 원자는 N, O 또는 S이며, 헤테로 사이클릭 환은 수소, C1-5알킬에 의해 임의로 치환된)또는 NR6R7[여기에서 R6및 R7은 독립적으로, 수소, C1-10알콕시카보닐 또는 비치환 또는 치환된 C1-10알킬 여기에서, 상기 치환체는 C1-10알콕시카보닐, 아릴, C4-10아르알킬이다)이다].(여기에서, N은 추가로 치환되어 4급 암모늄 이온을 형성할수 있다)이고; R2및 R3는 수소, R4는 아릴카보닐, C1-10알킬카보닐, 아르알킬카보닐, 아르알킬카보닐, C1-10알킬카보닐, C4-10아르알킬카보닐, 또는 C4-10아르알콕시카보닐이며, 또한 치환체 R4는 제1항에서 R6에 대해 정의한 그룹으로부터의 하나 이상의 치환체로 치환될수 있으며; R11는 수소 또는 C1-10알킬이고; X 및 Y는 독립적으로, NR6SO2, -SO2NR6-, 비치환 또는 치환된 C1-15직쇄 또는 측쇄 알킬(여기에서, 치환체는 하이드록시거나, N, O또는 S로부터 선택된, 1 또는 2개의 헤테로원자를 함유하는 4- 내지 6-원 헤테로 사이클릭 환이다)이며; 직쇄 또는 측쇄 알킬이고, m은 0내지 6의 정수이고 ; n은 0내지 6의 정수이며; p는 0내지 3의 정수이다.
- 하기 일반식(Ⅲ)는 화합물 및 이의 약제학적으로 허용가능한 염.상기 식에서 R1은, 1 또는 2개의 헤테로원자를 함유하는 6원의 헤테로사이클릭 환(여기에서 헤테로 원자는 N이고, 헤테로 사이클릭 환은 C1-5알킬에 의해 임의로 치환된)또는 NR6R7[여기에서 R6및 R7은 독립적으로, 수소 또는 C1-10알킬이다)이고, R4는 아릴카보닐, C1-10알킬카보닐,C4-10아르알킬카보닐,C1-10알콕시카보닐,C4-10아르알킬카보닐,C4-10아르알콕시카보닐이고, 또한, 치환체 R4는 제1항에서 R6로서 정의한 그룹으로부터의 하나 이상의 치환체로 치환될수 있으며, X 및 Y는 독립적으로, O,SO2, 아릴,-CH=CH- 또는 C1-10직쇄 또는 측쇄 알킬이고, Z는 임의의 치환체이며, 존재할 경우, O, 또는 C1-5직쇄 또는 측쇄 알킬이며, m은 0내지 6의 정수이고; n은 1이고;p는 0이다.
- 제1항에 있어서,2-S-(6-N-벤질옥시카보닐아미노)-3-[4-(3-클로로프로필옥시페닐]프로피온산; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(N,N,2,2-테트라메틸-1,3-프로판디아미노)프로필옥시페닐]프로피온산; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(3-N-피톨리디닐프로필옥시)페닐]프로피온산;2-S-(N-벤질옥시카보닐아미노)-4-[3-(N-메틸-N-벤질아미노프로필옥시페닐)프로피온산; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(4-피페라지닐)부틸옥시페닐]프로피온산; 2-S-(N-벤질옥시카보닐아미노)3-[4-(1,1,4,4-테트라메틸부틸아미노)필로필옥시페닐]프로피온산; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(4-메틸피페라진-1-일)필로필옥시페닐]프로피온산; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(5-브로모펜틸옥시)-페닐]프로피온산;2-S-(N-벤질옥시카보닐아미노)-3-[4-(4-피페라진-1-일)펜틸옥시페닐]프로피온산;2-S-(N-밴질옥시카보닐아미노)-3-[4-(6-아미노헥실옥시-페닐]프로피온산 하이드로클로라이드;2-S-(N-밴질옥시카보닐아미노)-3-[4-(7-아미노헥실옥시-페닐]프로피온산 하이드로클로라이드; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(8-아미노옥틸옥시-페닐)프로피온산;2-S-(N-벤질옥시카보닐아미노)-3-[4-(5-아미노헥실옥시-페닐]프로피온산 하이드로클로라이드; 2-S-(N-벤질옥시카보닐아미노)-3-[4-(4-피페리디닐-부틸옥시)페닐]프로피온산 ; 2-S-(페닐카보닐아미노-3-[4-(6-아미노헬실옥시)페닐]-프로피온산 하이드로클로클로라이드; 2-S-(페닐아세틸아미노)-3-[4-6-아미노헥실옥시)페닐]프로피온산; 2-S-(2-카복시-3-페닐프로리오닐아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산; 2-S-(헥사노닐아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산 하이드로클로라이드;2-S-(나프타노일아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산; 2-S-(부타노일아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산; 2-S-(헵타노일아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산 하이드로 클로라이드; 2-(S)-(5-페닐펜타노일아미노)-3-[6-t-부틸옥시카보닐아미노헥실옥시)페닐]프로피온산; 2-S-(5-페닐펜타노일아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산 하이드로클로라이드; 2-S-(3-카복시프로파노일)아미노-3-[4-(6-아미노헥실옥시)페닐]프로피온산 하이드로클로라이드; 2-S-(아세틸아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산 하이드로클로라이드; 2-S-(N-벤질옥시카보닐아미노)-3[4-(4-피페리디닐)-부트-2-에닐옥시페닐]프로피온산; 2-S-(N-t-벤질옥시카보닐아미노)-3-[4-(4-하이드록시부트-1-이닐)페닐]프로피온산; 2-S-(N-t-부틸옥시카보닐아미노)-3-[4-(4-하이드록시부틸)페닐]프로피온산; 2-S-(N-t-부틸옥시카보닐아미노)-3-[4-(4-t-부틸아미노부틸)페닐]프로피온산; 2-S-(펜타노일아미노)-3-[4-(4-피페리딘-4-일부틸옥시)-페닐]프로피온산 하이드로클로라이드; 2-S-(헥사노일아미노)-3-[4-(4-피페리딘-4-일부틸옥시)-페닐]프로피온산 ; 2-S-(5-아미노펜타노일)아미노-3-[4-(6-아미노헥실옥시)-페닐]프로피온산 하이드로클로라이드; 메틸 2-S-(4-카보메톡시부타노일)아미노-3-[4-(N-t-부틸옥시-카보닐아미오헥실옥시)페닐]프로피온산; 2-S-(4-카복시부타노일아미노)-3-[4-(6-아미노헥실옥시)-페닐]프로피온산; 및 2-S-(3-카복시프로파노일)아미노)-3-[4-(6-아미노헥실옥시)페닐]프로피온산 하이드로클로라이드 중에서 선택된 화합물.
- 포유동물에게 제1항에 다른 화합물을 약리학적 유효량으로 투여하는 단계를 포함함을 특징으로 하여, 포유동물에서 피브리노겐이 이의 수용체 부위에서 작용함을 차단하는 방법.
- 포유동물에게 제1항에 다른 화합물을 약리학적 유효량으로 투여하는 단계를 포함함을 특징으로 하여, 이를 필요로 하는 포유동물에서 혈전 및 색전형성을 예방하는 방법.
- 포유동물에게 제1항에 다른 화합물을 약리학적 유효량으로 투여하는 단계를 포함함을 특징으로 하여, 이를 필요로 하는 포유동물에서 혈전 및 색전형성을 치료하는 방법.
- 포유동물에게 제1항에 다른 화합물을 약리학적 유효량으로 투여하는 단계를 포함함을 특징으로 하여, 이를 필요로 하는 포유동물에서 혈소판의 응집을 억제시키는 방법.
- 제7항에 있어서, 상기 화합물을 항응고제와 공동 투여하는 방법.
- 제8항에 있어서, 상기 화합물을 항응고제와 공동 투여하는 방법.
- 제9항에 있어서, 상기 화합물을 항응고제와 공동 투여하는 방법.
- 제7항에 있어서, 상기 화합물을 혈전붕괴제와 공동 투여하는 방법.
- 제8항에 있어서, 상기 화합물을 혈전붕괴제와 공동 투여하는 방법.
- 제9항에 있어서, 상기 화합물을 혈전붕괴제와 공동 투여하는 방법.
- 제7항에 있어서, 상기 화합물을 혈소판 항응집제와 공동 투여하는 방법.
- 제8항에 있어서, 상기 화합물을 혈소판 항응집제와 공동 투여하는 방법
- 제9항에 있어서, 상기 화합물을 혈소판 항응집제와 공동 투여하는 방법
- 제7항에 다른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 약제학적 조성물.
- 제1항에 따른 화합물, 약제학적으로 허용가능한 담체 및 혈전붕괴제, 혈소판 항응집제 및 항응고제로 구성된 그룹으로부터 선택된 화합물을 함유함을 특징으로 하는 약제학적 조성물.
- 제20항에 있어서, 상기 약제학적으로 허용가능한 담체가 서방형 약제학적 제형으로 구성된 조성물.
- 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는, 포유동물에서 혈소판에 피브리노겐이 결합되는 것을 억제하기 위한 조성물.
- 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는, 포유동물에서 혈소판 응집 억제용 조성물.
- 혈전붕괴제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 특징으로 하는 포유동물에서의 혈소판응집 억제용 조성물.
- 항응고제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 예방용 조성물.
- 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 예방용 조성물.
- 혈전붕괴제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 치료용 조성물.
- 항응고제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 치료용 조성물.
- 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 치료용 조성물.
- 혈전붕괴제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 치료용 조성물.
- 항응고제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는 포유동물에서의 혈전 또는 색전 형성 치료용 조성물.
- 항혈소판제와 혼합된 제1항에 따른 화합물 및 약제학적으로 허용가능한 담체를 함유함을 특징으로 하는, 포유동물에서의 혈전 또는 색전 형성 치료용 조성물.
- 제20항에 따른 조성물을 포유동물에게 투여함을 특징으로 하여, 포유동물의 혈소판응집을 억제시키는 방법.
- 제21항에 따른 조성물을 포유동물에게 투여함을 특징으로 하여, 포유동물의 혈전, 색전형성을 예방하거나 치료하는 방법.
- 포유동물에서 피브리노겐이 혈소판과 결합하는 것을 억제시키고, 혈소판 응집을 억제시키며, 혈전 또는 색전 형성을 치료하거나 예방하는데 사용하기 위한 제1항에 따른 화합물.
- 포유동물에서 피브리노겐이 혈소판과 결합하는 것을 억제시키고, 혈소판 응집을 억제시키며, 혈전 또는 색전 형성을 치료하거나 예방하는데 사용하기 위한 제5항에 따른 화합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58929990A | 1990-09-27 | 1990-09-27 | |
US07/589,299 | 1990-09-27 | ||
US75064591A | 1991-08-30 | 1991-08-30 | |
US07/750,645 | 1991-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920006298A true KR920006298A (ko) | 1992-04-27 |
Family
ID=27080499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910016837A KR920006298A (ko) | 1990-09-27 | 1991-09-26 | 피브리노겐 수용체 길항제 |
Country Status (16)
Country | Link |
---|---|
US (1) | US5294616A (ko) |
EP (1) | EP0478328B1 (ko) |
JP (1) | JPH0819066B2 (ko) |
KR (1) | KR920006298A (ko) |
AT (1) | ATE132850T1 (ko) |
AU (1) | AU653360B2 (ko) |
CA (1) | CA2052069A1 (ko) |
DE (1) | DE69116285T2 (ko) |
DK (1) | DK0478328T3 (ko) |
ES (1) | ES2083534T3 (ko) |
FI (1) | FI914535A (ko) |
GR (1) | GR3018635T3 (ko) |
IE (1) | IE68955B1 (ko) |
IL (1) | IL99537A (ko) |
NO (1) | NO177703C (ko) |
PT (1) | PT99097B (ko) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8919504D0 (en) * | 1989-08-29 | 1989-10-11 | Leo Pharm Prod Ltd | Chemical compounds |
KR930703024A (ko) * | 1991-02-08 | 1993-11-29 | 리챠드 티. 딘 | 영상용 테크네튬-99m표지폴리펩티드 |
US6019958A (en) * | 1991-02-08 | 2000-02-01 | Diatide, Inc. | Technetium-99m labeled peptides for imaging inflammation |
US5736122A (en) * | 1991-02-08 | 1998-04-07 | Diatide, Inc. | Technetium-99m labeled peptides for thrombus imaging |
US6107459A (en) * | 1991-02-08 | 2000-08-22 | Diatide, Inc. | Technetium-99m labeled peptides for diagnostic imaging |
US5645815A (en) | 1991-02-08 | 1997-07-08 | Diatide, Inc. | Radiolabled compounds for thrombus imaging |
US5830856A (en) * | 1991-02-08 | 1998-11-03 | Diatide, Inc. | Radiolabeled compounds for thrombus imaging |
US5561220A (en) * | 1991-02-08 | 1996-10-01 | Diatech, Inc. | Technetium-99m labeled peptides for imaging inflammation |
HUT68769A (en) * | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
US5321034A (en) * | 1991-05-07 | 1994-06-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
PT100631B (pt) * | 1991-06-28 | 1999-06-30 | Smithkline Beecham Corp | Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem |
US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
US5204350A (en) * | 1991-08-09 | 1993-04-20 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives |
US5217994A (en) * | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
US5635477A (en) * | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
US5206373A (en) * | 1992-02-28 | 1993-04-27 | Merck & Co., Inc. | Process for preparing fibrinogen receptor antagonists |
US5968476A (en) * | 1992-05-21 | 1999-10-19 | Diatide, Inc. | Technetium-99m labeled peptides for thrombus imaging |
AU4540693A (en) * | 1992-06-25 | 1994-01-24 | G.D. Searle & Co. | Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors |
CA2144762A1 (en) * | 1992-10-14 | 1994-04-28 | George D. Hartman | Fibrinogen receptor antagonists |
US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
EP0664792B1 (en) * | 1992-10-14 | 2000-01-05 | Merck & Co. Inc. | Fibrinogen receptor antagonists |
US5358956A (en) * | 1992-10-14 | 1994-10-25 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5648368A (en) * | 1992-12-01 | 1997-07-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DE4302485A1 (de) * | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
US5409939A (en) * | 1993-02-12 | 1995-04-25 | G. D. Searle & Co. | Phenyl amidine thio derivatives useful as platelet aggregation inhibitors |
US5652242A (en) * | 1993-03-29 | 1997-07-29 | Zeneca Limited | Heterocyclic derivatives |
CA2156070A1 (en) * | 1993-03-29 | 1994-10-13 | Michael Garth Wayne | Heterocyclic derivatives as platelet aggregation inhibitors |
US5750754A (en) * | 1993-03-29 | 1998-05-12 | Zeneca Limited | Heterocyclic compounds |
US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
ZW4194A1 (en) * | 1993-03-29 | 1994-12-21 | Zeneca Ltd | Heterocyclic compounds |
US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
CA2363780C (en) * | 1993-04-08 | 2003-01-07 | Diatide, Inc. | Radiolabeled compounds for thrombus imaging |
US5334596A (en) * | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5612355A (en) * | 1993-06-23 | 1997-03-18 | G. D. Searle & Co. | Phenyl amidine lactones useful as platelet aggregation inhibitors |
GB9313285D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Acid derivatives |
US5463011A (en) * | 1993-06-28 | 1995-10-31 | Zeneca Limited | Acid derivatives |
GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
US6448269B1 (en) | 1993-07-22 | 2002-09-10 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
US6137002A (en) * | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DK0730589T3 (da) * | 1993-11-24 | 1999-02-01 | Du Pont Pharm Co | Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
US5523302A (en) * | 1993-11-24 | 1996-06-04 | The Du Pont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
EP0730590B1 (en) * | 1993-11-24 | 2001-01-17 | Dupont Pharmaceuticals Company | isoxazoline and isoxazole fibrinogen receptor antagonists |
US5446056A (en) * | 1993-11-24 | 1995-08-29 | The Du Pont Merck Pharmaceutical Company | Isoxazoline compounds useful as fibrinogen receptor antagonists |
US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
MA23420A1 (fr) * | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
US5821241A (en) * | 1994-02-22 | 1998-10-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
US6458784B1 (en) | 1994-06-29 | 2002-10-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US5451578A (en) * | 1994-08-12 | 1995-09-19 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5525617A (en) * | 1994-08-24 | 1996-06-11 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5494921A (en) * | 1994-09-16 | 1996-02-27 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5719144A (en) * | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ZA963391B (en) * | 1995-05-24 | 1997-10-29 | Du Pont Merck Pharma | Isoxazoline fibrinogen receptor antagonists. |
US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
US6100423A (en) * | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
CA2230209A1 (en) | 1995-08-30 | 1997-03-06 | G.D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
WO1997014417A1 (en) * | 1995-10-19 | 1997-04-24 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5789421A (en) * | 1995-10-26 | 1998-08-04 | Merck & Co., Inc. | Fibrinogen receptor antagonist |
DE19548709A1 (de) * | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
US5952306A (en) * | 1996-01-16 | 1999-09-14 | Merck & Co., Inc. | Integrin receptor antagonists |
JP2000505471A (ja) * | 1996-02-28 | 2000-05-09 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲン受容体拮抗物質 |
US5780480A (en) * | 1996-02-28 | 1998-07-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ATE219764T1 (de) * | 1996-03-29 | 2002-07-15 | Searle & Co | Zimtsäurederivate und deren verwendung als integrin-antagonisten |
PT891325E (pt) * | 1996-03-29 | 2002-07-31 | Searle & Co | Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina |
DE69706407T2 (de) * | 1996-03-29 | 2002-05-29 | Searle & Co | META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN |
DE69705300T2 (de) * | 1996-03-29 | 2002-05-02 | Searle & Co | Cyclopropylalkansäurederivate |
EP0889876B1 (en) | 1996-03-29 | 2001-07-25 | G.D. SEARLE & CO. | Meta-substituted phenylene sulphonamide derivatives |
US5889023A (en) * | 1996-05-10 | 1999-03-30 | Merck & Co., Inc. | Fibrinogen receptor antagonist |
JP2000515133A (ja) | 1996-07-01 | 2000-11-14 | イーライ・リリー・アンド・カンパニー | 血糖降下性および脂質低下性の化合物 |
US6004955A (en) * | 1996-08-15 | 1999-12-21 | Dupont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists |
GB2318053A (en) * | 1996-10-08 | 1998-04-15 | Merck & Co Inc | Angioplasty procedure using nonionic contrast media |
US5981584A (en) * | 1997-02-06 | 1999-11-09 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
US6294549B1 (en) | 1997-07-23 | 2001-09-25 | Merck & Co., Inc. | Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect |
PL339660A1 (en) | 1997-10-02 | 2001-01-02 | Sankyo Co | Derivatives of amidocarboxylic acids |
IL136267A0 (en) * | 1997-11-26 | 2001-05-20 | Du Pont Pharm Co | 1,3,4-THIADIZOLES AND 1,3,4-OXADIAZOLES AS αVβ3 ANTAGONISTS |
JPH11279040A (ja) | 1998-03-27 | 1999-10-12 | Kao Corp | 皮膚外用剤 |
JP2003504301A (ja) | 1998-04-01 | 2003-02-04 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | インテグリンアンタゴニスト |
EP1091945A1 (en) | 1998-06-29 | 2001-04-18 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
US6204282B1 (en) | 1998-11-30 | 2001-03-20 | Schering Corporation | Benzimidazole compounds that are vitronectin receptor antagonists |
US6808698B1 (en) | 1999-03-26 | 2004-10-26 | Bristol-Myers Squibb Pharma Company | Method for localization of blood clots |
US6348504B1 (en) | 1999-03-30 | 2002-02-19 | Richard E. Olson | Oxime ethers as IIb/IIa antagonists |
US6375948B1 (en) * | 1999-07-12 | 2002-04-23 | Kao Corporation | Treating method for suppressing hair growth |
US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
US6685914B1 (en) | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
US6518244B2 (en) | 2000-03-09 | 2003-02-11 | Intimax Corporation | Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof |
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
PE20020665A1 (es) | 2000-06-15 | 2002-08-14 | Pharmacia Corp | ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
AR039156A1 (es) | 2002-03-28 | 2005-02-09 | Novartis Ag | Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide |
US7317104B2 (en) | 2003-06-13 | 2008-01-08 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
US7319149B2 (en) | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
CA3005835C (en) * | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
JP2009516730A (ja) * | 2005-11-23 | 2009-04-23 | アストラゼネカ アクチボラグ | L−アラニン誘導体 |
EP2049490A1 (en) * | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
US20090062267A1 (en) * | 2007-01-29 | 2009-03-05 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS |
WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
JP6630671B2 (ja) | 2013-12-18 | 2020-01-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーター |
CN103708392A (zh) * | 2013-12-31 | 2014-04-09 | 中国重型机械研究院股份公司 | 一种可实现全自动控制的钢卷翻卷机 |
CN104693096A (zh) * | 2015-02-13 | 2015-06-10 | 佛山市赛维斯医药科技有限公司 | 含双酰肼和萘基结构的化合物、制备方法及其用途 |
CN104693102A (zh) * | 2015-02-13 | 2015-06-10 | 佛山市赛维斯医药科技有限公司 | 一种双酰肼类化合物、其制备方法及其用途 |
PL3307739T3 (pl) | 2015-06-15 | 2021-05-31 | Glaxosmithkline Intellectual Property Development Limited | Regulatory nrf2 |
JP6786527B2 (ja) | 2015-06-15 | 2020-11-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーター |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1062206B (it) * | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | Derivati della tirosina attivi sulla muscolatura liscia |
DE2549999A1 (de) * | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | Piperidin-derivate und verfahren zu ihrer herstellung |
US4064125A (en) * | 1976-10-29 | 1977-12-20 | E. R. Squibb And Sons, Inc. | Substituted amides having antiinflammatory activity |
EP0021592B1 (en) * | 1979-05-23 | 1983-09-28 | BEECHAM - WUELFING GmbH & Co. KG | Phenylsulphonamide derivatives, a process for their preparation and their use as medicines |
US4479942A (en) * | 1981-08-10 | 1984-10-30 | Fujisawa Pharmaceutical Co., Ltd. | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof |
KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
CA2008116C (en) * | 1989-02-23 | 2001-11-20 | Thomas Weller | Glycine derivatives |
DE4009506A1 (de) * | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
-
1991
- 1991-09-20 IL IL9953791A patent/IL99537A/en active IP Right Grant
- 1991-09-23 CA CA002052069A patent/CA2052069A1/en not_active Abandoned
- 1991-09-26 ES ES91308793T patent/ES2083534T3/es not_active Expired - Lifetime
- 1991-09-26 KR KR1019910016837A patent/KR920006298A/ko not_active Application Discontinuation
- 1991-09-26 IE IE338291A patent/IE68955B1/en not_active IP Right Cessation
- 1991-09-26 DE DE69116285T patent/DE69116285T2/de not_active Expired - Fee Related
- 1991-09-26 PT PT99097A patent/PT99097B/pt not_active IP Right Cessation
- 1991-09-26 EP EP91308793A patent/EP0478328B1/en not_active Expired - Lifetime
- 1991-09-26 DK DK91308793.8T patent/DK0478328T3/da active
- 1991-09-26 FI FI914535A patent/FI914535A/fi not_active Application Discontinuation
- 1991-09-26 AU AU84788/91A patent/AU653360B2/en not_active Ceased
- 1991-09-26 AT AT91308793T patent/ATE132850T1/de not_active IP Right Cessation
- 1991-09-26 NO NO913787A patent/NO177703C/no not_active IP Right Cessation
- 1991-09-27 JP JP3318723A patent/JPH0819066B2/ja not_active Expired - Lifetime
-
1992
- 1992-03-25 US US07/857,528 patent/US5294616A/en not_active Expired - Fee Related
-
1996
- 1996-01-11 GR GR950403582T patent/GR3018635T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0478328B1 (en) | 1996-01-10 |
JPH05155828A (ja) | 1993-06-22 |
ATE132850T1 (de) | 1996-01-15 |
IL99537A (en) | 1995-11-27 |
FI914535A0 (fi) | 1991-09-26 |
US5294616A (en) | 1994-03-15 |
FI914535A (fi) | 1992-03-28 |
PT99097A (pt) | 1992-08-31 |
NO177703B (no) | 1995-07-31 |
EP0478328A1 (en) | 1992-04-01 |
IE68955B1 (en) | 1996-07-24 |
NO913787L (no) | 1992-03-30 |
AU8478891A (en) | 1992-04-02 |
DE69116285D1 (de) | 1996-02-22 |
GR3018635T3 (en) | 1996-04-30 |
DE69116285T2 (de) | 1996-10-17 |
PT99097B (pt) | 1999-02-26 |
IE913382A1 (en) | 1992-04-08 |
AU653360B2 (en) | 1994-09-29 |
DK0478328T3 (da) | 1996-02-05 |
NO177703C (no) | 1995-11-08 |
NO913787D0 (no) | 1991-09-26 |
ES2083534T3 (es) | 1996-04-16 |
JPH0819066B2 (ja) | 1996-02-28 |
CA2052069A1 (en) | 1992-03-28 |
IL99537A0 (en) | 1992-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920006298A (ko) | 피브리노겐 수용체 길항제 | |
US11793798B2 (en) | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | |
KR950032037A (ko) | 신규의 델타-아미노-감마-히드록시-오메가-아릴-알칸산 아미드 | |
KR920006313A (ko) | 설폰아미드 피브리노겐 수용체 길항제 | |
KR930009993A (ko) | 혈전증 치료제 | |
RU99105567A (ru) | Производные пропионовой кислоты и их использование | |
TNSN90003A1 (fr) | Derives de 2-aminopyrimidinones utiles notamment comme antagonistes des neurotransmetteurs et procede pour leur preparation | |
WO2001090070A3 (en) | Caspase inhibitors and uses thereof | |
SK10095A3 (en) | Injection and injection kit containing omeprazole and its analogs | |
PL1683524T3 (pl) | Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny | |
KR960022449A (ko) | 방향족 치환된 ω-아미노-알칸산 아미드 및 알칸산 디아미드 | |
CA2475619A1 (en) | Piperidine derivatives | |
MXPA06012655A (es) | Preparaciones topicas que contienen ambroxol. | |
KR20170129170A (ko) | 서방성 의약 조성물 | |
RU96109467A (ru) | Новые соединения, обладающие способностью ингибировать агрегацию тромбоцитов | |
US5066664A (en) | 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents | |
KR100215533B1 (ko) | 아르기닌 아미드 함유 의약 조성물 | |
CA2237898A1 (en) | Combination therapy for treating glaucoma | |
KR930002319A (ko) | Aids 치료에 유용한 hiv 프로테아제의 억제제 | |
US4705781A (en) | Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof | |
TWI794140B (zh) | 含有吡啶基胺基乙酸化合物之預防及/或治療劑 | |
US11666563B2 (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
RU98106104A (ru) | Производные пиримидина | |
KR880001593A (ko) | 4-(아로일아미노)피페리딘부탄아미드 유도체 | |
US7320982B2 (en) | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |